Literature DB >> 2665935

Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.

G Masucci1, P Wersäll, P Ragnhammar, H Mellstedt.   

Abstract

Human peripheral blood mononuclear cells (lymphocytes and monocytes) were preincubated for 0-24 h with human recombinant granulocyte-monocyte-colony-stimulating factor (GM-CSF) and used as effector cells in an 18 h antibody-dependent cellular cytotoxicity (ADCC) assay with SW948 (a human colorectal carcinoma cell line) as target cells and mAb 17-1A. A significant increase in the lytic capability was noted after 0.5-2 h of preactivation while longer preincubation times did not significantly increase the lytic potential. GM-CSF at 0.01 microgram/ml induced the best tumor cell lysis while higher concentrations were inhibitory. GM-CSF pretreatment induced a statistically significant increase in the lytic capacity of both monocytes and lymphocytes in ADCC as well as in the spontaneous cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2665935     DOI: 10.1007/bf00199217

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  30 in total

1.  Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor.

Authors:  D S Silberstein; W F Owen; J C Gasson; J F DiPersio; D W Golde; J C Bina; R Soberman; K F Austen; J R David
Journal:  J Immunol       Date:  1986-11-15       Impact factor: 5.422

2.  Anti-idiotypic monoclonal antibody to a T-cell chronic lymphatic leukemia. Characterization of the antibody, in vitro effector functions and results of therapy.

Authors:  C H Janson; M J Tehrani; H Mellstedt; H Wigzell
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Interleukin 1 and T-cell activation.

Authors:  S B Mizel
Journal:  Immunol Today       Date:  1987

4.  Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor.

Authors:  K H Grabstein; D L Urdal; R J Tushinski; D Y Mochizuki; V L Price; M A Cantrell; S Gillis; P J Conlon
Journal:  Science       Date:  1986-04-25       Impact factor: 47.728

5.  In vitro studies of lymphocytes from patients with plasma cell myeloma. I. Stimulation by mitogens and cytotoxic activities.

Authors:  H Mellstedt; G Holm
Journal:  Clin Exp Immunol       Date:  1973-11       Impact factor: 4.330

6.  Quantitative studies on phytohaemagglutinin-induced cytotoxicity by human lymphocytes against homologous cells in tissue culture.

Authors:  G Holm; P Perlmann
Journal:  Immunology       Date:  1967-05       Impact factor: 7.397

7.  Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma.

Authors:  D Herlyn; M Herlyn; Z Steplewski; H Koprowski
Journal:  Eur J Immunol       Date:  1979-08       Impact factor: 5.532

8.  The interaction of murine IgG subclass proteins with human monocyte Fc receptors.

Authors:  M D Lubeck; Z Steplewski; F Baglia; M H Klein; K J Dorrington; H Koprowski
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

9.  Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF.

Authors:  R E Donahue; E A Wang; D K Stone; R Kamen; G G Wong; P K Sehgal; D G Nathan; S C Clark
Journal:  Nature       Date:  1986 Jun 26-Jul 2       Impact factor: 49.962

10.  Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.

Authors:  J R Ortaldo; C Woodhouse; A C Morgan; R B Herberman; D A Cheresh; R Reisfeld
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

View more
  18 in total

Review 1.  Combination strategies to enhance antitumor ADCC.

Authors:  Holbrook E Kohrt; Roch Houot; Aurélien Marabelle; Hearn Jay Cho; Keren Osman; Matthew Goldstein; Ronald Levy; Joshua Brody
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

2.  Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study.

Authors:  Giuseppe Masucci; Peter Broman; Charles Kelly; Sten Lindahl; Lena Malmberg; Johan Reizenstein; Martin Alenius; Rolf Lewensohn
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

3.  Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).

Authors:  G Masucci; P Ragnhammar; P Wersäll; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.

Authors:  Susan M Grant; Rennie C Heel
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

Review 5.  Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy.

Authors:  P Ragnhammar; M Wadhwa
Journal:  Med Oncol       Date:  1996-09       Impact factor: 3.064

Review 6.  Granulocyte-macrophage colony-stimulating factor and the immune system.

Authors:  P E Tarr
Journal:  Med Oncol       Date:  1996-09       Impact factor: 3.064

Review 7.  Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors.

Authors:  P Ragnhammar
Journal:  Med Oncol       Date:  1996-09       Impact factor: 3.064

8.  Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.

Authors:  D Flieger; A S Hoff; T Sauerbruch; I G Schmidt-Wolf
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

Review 9.  Chemotherapy and immunotherapy of colorectal cancer.

Authors:  G Masucci; P Ragnhammar; J E Frödin; A L Hjelm; P Wersäll; J Fagerberg; A Osterborg; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

10.  The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma (CRC).

Authors:  P Ragnhammar; I Magnusson; G Masucci; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.